<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178578">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770328</url>
  </required_header>
  <id_info>
    <org_study_id>030497</org_study_id>
    <nct_id>NCT00770328</nct_id>
  </id_info>
  <brief_title>The Effects of Pentoxifylline on PAI-1 in an Obese Population</brief_title>
  <official_title>The Effects of Pentoxifylline on PAI-1 in an Obese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PAI-1 is elevated in obese individuals. TNF-alpha, an inflammatory mediator is believed to
      play a role in obesity mediated elevations in PAI-1 levels. TNF-alpha blockade with
      antibodies and the drug pentoxifylline have been shown to lower PAI-1 levels in animal
      models. This study tests the hypothesis that pentoxifylline will lower PAI-1 levels in human
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese individuals with elevated PAI-1 levels (greater than 10 ng/ml) are randomized to
      pentoxifylline 400mg, TID or placebo for 8 weeks. PAI-1, TNF-a and high sensitivity
      C-Reactive Protein are measured at week 0, 4 and 8.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2003</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PAI-1 level</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CRP level</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TNF-alpha level</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the relationship between PAI-1, CRP, and TNF-a with therapy.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Pentoxifylline 400 mg po TID for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients take a placebo TID for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400mg PO TID x 8 weeks</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PO TID x 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusions: 1. A Body Mass Index of ≥ 30.0 2. Age 21 or older 3. Few or no medical
        problems 4. PAI-1 level ≥ 10 ng/dl

        Exclusions: 1. Cigarette use 2. Present use of ACE Inhibitors 3. Recent cerebral and/or
        retinal hemorrhage 4. Intolerance to pentoxifylline or methylxanthines such as caffeine,
        theophylline, and theobromine 5. Presently on warfarin therapy 6. Pregnancy or
        breast-feeding 7. Recent surgery 8. Recent diagnosis/treatment for peptic ulcer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A S Muldowney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <lastchanged_date>January 27, 2009</lastchanged_date>
  <firstreceived_date>October 9, 2008</firstreceived_date>
  <responsible_party>
    <name_title>James Muldowney, M.D., F.A.C.C., Assistant Professor of Medicine</name_title>
    <organization>Vanderbilt University School of Medicine</organization>
  </responsible_party>
  <keyword>Plasma PAI-1 level at 0, 4, 8 weeks</keyword>
  <keyword>Plasma hsCRP level at 0, 4, 8 weeks</keyword>
  <keyword>Plasma TNF-a level at 0, 4, 8 weeks</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
